TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$13.14
−1.72%Aug 18, 2026, 07:02 UTC
Tonix Pharmaceuticals is focusing on the commercial launch of TONMYA for fibromyalgia.
Source:Aug 18, 2026, 00:00 UTC
Dr. Seth Lederman was appointed Interim Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., effective August 18, 2026, while continuing as President, Chief Executive Officer and Chairman of the Board.
Aug 10, 2026, 11:00 UTC
Tonix Pharmaceuticals reported second quarter 2026 financial results, with TONMYA net sales of approximately $11 million, up 197% quarter-over-quarter, and cash and cash equivalents of approximately $176.2 million as of June 30, 2026.
Aug 3, 2026, 11:00 UTC
Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting regarding the adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody to prevent Lyme disease in the U.S.
Source:Jul 13, 2026, 11:00 UTC
Tonix Pharmaceuticals announced a managed Medicare payer agreement for TONMYA, effective January 1, 2027, covering approximately 9 million Medicare lives.
Source:Jun 8, 2026, 12:41 UTC
Tonix Pharmaceuticals secured a second commercial payer agreement for its fibromyalgia treatment TONMYA.
Source: